Eli Lilly reported late‑stage clinical data showing its triple‑agonist retatrutide produced substantial weight loss and clinically meaningful HbA1c reductions in patients with type 2 diabetes. The company disclosed topline Phase 3 results showing double‑digit percentage weight loss and up to a 1.9 percentage‑point drop in HbA1c, positioning the drug as a potential competitor to current GLP‑1/GIP therapies. The data provide both metabolic and weight‑loss signals of interest to regulators and payers; Lilly fielded analyst attention and has begun framing retatrutide for dual diabetes‑and‑obesity use. Retatrutide’s results were reported by Lilly and summarized in major trade coverage (STAT, company releases) with detailed efficacy and safety readouts expected in peer materials and regulatory filings. Clarification: retatrutide is a multi‑receptor agonist designed to target GLP‑1, GIP and glucagon pathways to amplify weight‑loss and glycemic control beyond single‑agonist therapies.